In today’s highly regulated healthcare environment, commercial compliance has become among the most pressing topics on the minds of pharmaceutical and medical device executives. Yet, there is no single publication that goes deep enough to shed light on the myriad issues facing these executives, according to Thomas Sullivan, Editor ofPolicy & Medicine, the leading daily information resource on life science compliance.
“It seems that in every pharma meeting–no matter what topic–half the discussion is focused around compliance,” said Sullivan. “Whether it’s the Sunshine Act or implementing CIAs or the Anti-Kickback Statute or False Claims Act, there’s a lot of talk about what’s important and what companies should be doing to meet standards.”
To address this growing concern, Policy & Medicine today published the premiere issue of Life Science Compliance Update, a monthly subscription publication that seeks to demystify commercial compliance and bring important new understanding to healthcare organizations. Life Science Compliance Update is the only monthly dedicated exclusively to commercial compliance that goes beyond news to offer practicable analysis of current happenings. Although it goes more in-depth than any other outlet in its field, it is remarkably concise and can be read in its entirety in 20 minutes or less.
“Our goal was to create a single resource that allows busy executives to read less but become more attuned,” said Sullivan, who also serves as Editor for Life Science Compliance Update. “When readers finish an issue they’ll have a clear understanding of what has been happening in the last six months, why certain actions are important and why they are of concern to their organizations.”
Given the enormous risks compliance violations pose to an organization, it is important now more than ever for compliance executives to know what is happening outside of their companies and to better promote ‘big picture’ thinking. “Almost every day there is a new requirement that we need to be looking out for that even just weeks before no one even considered,” added Sullivan.
For organizations large and small, the new publication also helps bridge knowledge gaps that may occur as a result of staff turnover or limited resources within the compliance function. “Even companies with the most experienced and knowledgeable compliance officers are finding it difficult to communicate their knowledge to those below them,” continued Sullivan. “They can lay out the policies and procedures but this new resource will help answer some of the why that has been missing from the conversation.”
A diverse Editorial Board comprised of compliance experts from leading pharmaceutical and medical devices companies, law firms, compliance service and consulting firms, and associations has been assembled to support the publication’s editorial direction. Target readership includes compliance officers and medical affairs departments at pharmaceutical and medical device companies, law firms, compliance technology companies, governmental compliance employees and others. The publishers also plan to accept submitted articles to round out coverage of diverse and timely topics.
April 2015 Issue
Available now, the April 2015 premiere issue of Life Science Compliance Update covers the latest enforcement trends coming out of the Department of Justice, a comprehensive update on HHS-OIG activity, and a thorough breakdown of important state transparency laws and new state bills that could have a big impact on life science companies. The featured article in April’s issue provides the most comprehensive review and analysis of states’ “Right to Try” acts available. Comparing the States’ “Right To Try” Acts: Effective Legislation or False Hope? was written by David Vulcano, industry regulatory expert and the Responsible Executive for Clinical Research at the Hospital Corporation of America.
Table of Contents
-
- The Media Has Been All Over “Bad Pharma” This Year, But Has the Department of Justice Followed Suit?
- Daiichi Sankyo and Speaker Programs
- AstraZeneca and Pharmacy Benefit Managers
-
- Pharmaceutical and Device Corporate Integrity Agreements: Who’s In, Who’s Out?
- Quick Take: Recent HHS-OIG Activity
-
- Update on State Reporting Activity After Implementation of the Federal Physician Payments Sunshine Act
- The Wild West: California and Oregon Introduce Drug Cost Transparency Bills
-
- Comparing the States’ “Right to Try” Acts: Effective Legislation of False Hope? by David Vulcano, Responsible Executive for Clinical Research at HCA
Subscription
An annual individual subscription of 12 electronic issues is available for $1,200.00 U.S, with multiple subscriber-based discounts available. To learn more and to purchase, visit www.lifescicompliance.com. A free sample issue also is available for download by visiting www.lifescicompliance.com.
About Life Science Compliance Update
From the publishers of Policy & Medicine (www.policymed.com), Life Science Compliance Update (www.lifescicompliance.com) is the industry’s first monthly publication to venture beyond regulatory news to bring a deeper understanding of the key commercial compliance issues facing life science executives today. Founded by Thomas Sullivan, one of the industry’s leading compliance experts and Editor of Policy & Medicine, Life Science Compliance Update offers readers the most concise, practicable analysis of current happenings in the world of compliance.
About Policy & Medicine
Policy & Medicine offers a daily look at regulatory issues affecting the pharmaceutical and device industry. Since its inception in 2008,Policy & Medicine has become one of the most widely followed websites in its field. Policy & Medicine provides detailed analysis of many important compliance issues, and is one of the leading resources for information on the Physician Payments Sunshine Act. BothPolicy & Medicine and Life Science Compliance Update are owned by Columbia, Maryland-based Rockpointe Corp., a science-based medical education company. For more information visit www.policymed.com or www.rockpointe.com.